Tamsin Kate Phillips

Tamsin Kate Phillips

Auto-generated profile, based on publicly available information

Tamsin Kate Phillips

University of Cape Town

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
TPTamsin Phillips
Tamsin Phillips
ETElizabeth Thebus
Elizabeth Thebus
LBLinda‐Gail Bekker
Linda‐Gail Bekker
JMJames McIntyre
James McIntyre
EAElaine J Abrams
Elaine J Abrams
LMLandon Myer
Landon Myer
Introduction: Recent international guidelines call for expanded access to triple‐drug antiretroviral therapy (ART) in HIV‐positive women during pregnancy and postpartum. However, high levels of non‐adherence and/or disengagement from care may attenuate the benefits of ART for HIV transmission and maternal health. We examined the frequency and predictors of disengagement from care among women initiating ART during pregnancy in Cape Town, South Africa.Methods: We used routine medical records to follow‐up pregnant women initiating ART within prevention of mother‐to‐child transmission of HIV services in Cape Town, South Africa. Outcomes assessed through six months postpartum were (1) disengagement (no attendance within 56 days of a scheduled visit) and (2) missed visits (returning to care 14–56 days late for a scheduled visit).Results: A total of 358 women (median age, 28 years; median gestational age, 26 weeks) initiated ART during pregnancy. By six months postpartum, 24% of women (n=86) had missed at least one visit and an additional 32% (n=115) had disengaged from care; together, 49% of women had either missed a visit or had disengaged by six months postpartum. Disengagement was more than twice as frequent postpartum compared to in the antenatal period (6.2 vs. 2.4 per 100 woman‐months, respectively; p<0.0001). In a proportional hazards model, later gestational age at initiation (HR: 1.04; 95% CI: 1.00–1.07; p=0.030) and being newly diagnosed with HIV (HR: 1.57; 95% CI: 1.07–2.33; p=0.022) were significant predictors of disengagement after adjusting for patient age, starting CD4 cell count and site of ART initiation.Conclusions: These results demonstrate that missed visits and disengagement from care occur frequently, particularly post‐delivery, among HIV‐positive women initiating ART during pregnancy. Women who are newly diagnosed with HIV may be particularly vulnerable and there is an urgent need for interventions both to promote retention overall, as well as targeting women newly diagnosed with HIV during pregnancy.

28 July 2017 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
TMThokozile R Malaba
Thokozile R Malaba
TPTamsin Phillips
Tamsin Phillips
SRStanzi Le Roux
Stanzi Le Roux
KBKirsty Brittain
Kirsty Brittain
AZAllison Zerbe
Allison Zerbe
LMLandon Myer
Landon Myer
Studies of antiretroviral therapy (ART) use during pregnancy in HIV-infected women have suggested that ART exposure may be associated with adverse birth outcomes. However, there are few data from sub-Saharan Africa where HIV is most common, and few studies involving the World Health Organization’s (WHO’s) recommended first-line regimens. We enrolled consecutive HIV-infected pregnant women and a comparator cohort of uninfected women at a primary-level antenatal care facility in Cape Town, South Africa. Gestational assessment combined clinical history, examination and ultrasonography; outcomes included preterm (PTD), low birthweight (LBW) and small for gestational age (SGA) deliveries. In analysis we compared birth outcomes between HIV-infected and -uninfected women, and HIV-infected women who initiated ART before vs during pregnancy. In 1554 women (mean age 29 years) with live singleton births at time of analysis, 82% were HIV-infected, 92% of whom received a first-line regimen of tenofovir, emtricitabine and efavirenz. Overall, higher levels of PTD [22% vs 13%; odds ratio (OR) 1.94, 95% confidence interval (CI): 1.34, 2.82] and LBW (14% vs 9%; OR 1.62, 95% CI: 1.05, 2.29) were observed in HIV-infected vs uninfected women, although SGA deliveries were similar (9% vs 11%; OR 1.06, 95% CI: 0.71, 1.61). Adjusting for demographic characteristics and HIV disease measures, HIV-infected (vs HIV-uninfected) women had persistently increased odds of PTD [adjusted odds ratio (AOR) 2.03; CI 1.33, 3.10]; associations with LBW were attenuated (AOR 1.47; CI 0.90, 2.40). Among all HIV-infected women, there appeared to be no association between the timing of ART initiation (before or during pregnancy) and adverse birth outcomes. These findings suggest that current WHO-recommended ART regimens appear relatively safe in pregnancy, although more data are required to understand the aetiology of preterm delivery in HIV-infected women using ART.

6 April 2016 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
KBKirsty Brittain
Kirsty Brittain
CMClaude A. Mellins
Claude A. Mellins
TPTamsin Phillips
Tamsin Phillips
AZAllison Zerbe
Allison Zerbe
EAElaine J. Abrams
Elaine J. Abrams
RRRobert H. Remien
Robert H. Remien

1 April 2019 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
SRStanzi M le Roux
Stanzi M le Roux
EAElaine J Abrams
Elaine J Abrams
KDKirsten A Donald
Kirsten A Donald
KBKirsty Brittain
Kirsty Brittain
TPTamsin K Phillips
Tamsin K Phillips
LMLandon Myer
Landon Myer

30 March 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
LMLandon Myer
Landon Myer
TPTamsin K Phillips
Tamsin K Phillips
AZAllison Zerbe
Allison Zerbe
KBKirsty Brittain
Kirsty Brittain
MLMaia Lesosky
Maia Lesosky
EAElaine J Abrams
Elaine J Abrams
As the number of HIV-infected women initiating lifelong antiretroviral therapy (ART) during pregnancy increases globally, concerns have emerged regarding low levels of retention in HIV services and suboptimal adherence to ART during the postpartum period. We examined the impact of integrating postpartum ART for HIV+ mothers alongside infant follow-up within maternal and child health (MCH) services in Cape Town, South Africa. We conducted a randomised trial among HIV+ postpartum women aged ≥18 years who initiated ART during pregnancy in the local antenatal care clinic and were breastfeeding when screened before 6 weeks postpartum. We compared an integrated postnatal service among mothers and their infants (the MCH-ART intervention) to the local standard of care (control)—immediate postnatal referral of HIV+ women on ART to general adult ART services and their infants to separate routine infant follow-up. Evaluation data were collected through medical records and trial measurement visits scheduled and located separately from healthcare services involved in either arm. The primary trial outcome was a composite endpoint of women’s retention in ART care and viral suppression (VS) (viral load < 50 copies/ml) at 12 months postpartum; secondary outcomes included duration of any and exclusive breastfeeding, mother-to-child HIV transmission, and infant mortality. Between 5 June 2013 and 10 December 2014, a total of 471 mother–infant pairs were enrolled and randomised (mean age, 28.6 years; 18% nulliparous; 57% newly diagnosed with HIV in pregnancy; median duration of ART use at randomisation, 18 weeks). Among 411 women (87%) with primary endpoint data available, 77% of women (n = 155) randomised to the MCH-ART intervention achieved the primary composite outcome of retention in ART services with VS at 12 months postpartum, compared to 56% of women (n = 117) randomised to the control arm (absolute risk difference, 0.21; 95% CI: 0.12–0.30; p < 0.001). The findings for improved retention in care and VS among women in the MCH-ART intervention arm were consistent across subgroups of participants according to demographic and clinical characteristics. The median durations of any breastfeeding and exclusive breastfeeding were longer in women randomised to the intervention versus control arm (6.9 versus 3.0 months, p = 0.006, and 3.0 versus 1.4 months, p < 0.001, respectively). For the infants, overall HIV-free survival through 12 months of age was 97%: mother-to-child HIV transmission was 1.2% overall (n = 4 and n = 1 transmissions in the intervention and control arms, respectively), and infant mortality was 1.9% (n = 6 and n = 3 deaths in the intervention and control arms, respectively), and these outcomes were similar by trial arm. Interpretation of these findings should be qualified by the location of this study in a single urban area as well as the self-reported nature of breastfeeding outcomes. In this study, we found that integrating ART services into the MCH platform during the postnatal period was a simple and effective intervention, and this should be considered for improving maternal and child outcomes in the context of HIV. ClinicalTrials.gov NCT01933477.

24 August 2018 in AIDS
Verified
Journal Article
Closed access
SRStanzi M. le Roux
Stanzi M. le Roux
KDKirsten A Donald
Kirsten A Donald
KBKirsty Brittain
Kirsty Brittain
TPTamsin K. Phillips
Tamsin K. Phillips
AZAllison Zerbe
Allison Zerbe
LMLandon Myer
Landon Myer
Objectives: To assess neurodevelopment of breastfed HIV-exposed uninfected (HEU) and breastfed HIV-unexposed children in the context of universal maternal antiretroviral therapy (ART). Design: Prospective study with antenatal enrolment and follow-up of breastfeeding HEU and HIV-unexposed mother–infant pairs through 12–18 months postpartum. Setting: Peri-urban community, Cape Town, South Africa. Participants: HEU (n = 215) and HIV-unexposed (n = 306) children. Main outcome measures: Cognitive, motor and language development at median 13 (interquartile range 12–14) months of age: continuous and dichotomous Bayley Scales of Infant and Toddler Development Third Edition (delay defined as composite score <85). Results: Incidence of preterm delivery (<37 weeks) was similar among HEU and HIV-unexposed children (11 vs. 9%, P = 0.31; median gestation 39 weeks); 48% were boys. Median breastfeeding duration was shorter among HEU vs. HIV-unexposed children (6 vs. 10 months). All HIV-infected mothers initiated lifelong ART (tenofovir–emtricitabine–efavirenz) antenatally. HEU (vs. HIV-unexposed) children had higher odds of cognitive delay [odds ratio (OR) 2.28 (95% confidence interval (CI) 1.13–4.60)] and motor delay [OR 2.10 (95% CI 1.03–4.28)], but not language delay, in crude and adjusted analysis. Preterm delivery modified this relationship for motor development: compared with term HIV-unexposed children, term HEU children had similar odds of delay, preterm HIV-unexposed children had five-fold increased odds of delay (adjusted OR 4.73, 95% CI 1.32; 16.91) and preterm HEU children, 16-fold increased odds of delay (adjusted OR 16.35, 95% CI 5.19; 51.54). Conclusion: Young HEU children may be at increased risk for cognitive and motor delay despite universal maternal ART and breastfeeding; those born preterm may be particularly vulnerable.